83 related articles for article (PubMed ID: 33877777)
1. Treatment patterns for patients with advanced/metastatic cancers by site of care.
Bunniran S; Xu Y; Molife C; Nair R; Zhu YE; Carter GC; Sheth S; Hess LM
Am J Manag Care; 2021 Apr; 27(4):e105-e113. PubMed ID: 33877777
[TBL] [Abstract][Full Text] [Related]
2. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
3. Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States?
Hopson S; Casebeer A; Stemkowski S; Antol DD; Tao Z; Howe A; Patton J; Small A; Masaquel A
J Med Econ; 2018 Feb; 21(2):152-162. PubMed ID: 28945163
[TBL] [Abstract][Full Text] [Related]
4. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
Goyal RK; Carter GC; Nagar SP; Smyth EN; Price GL; Huang YJ; Li L; Davis KL; Kaye JA
Curr Med Res Opin; 2019 Oct; 35(10):1699-1710. PubMed ID: 31060392
[No Abstract] [Full Text] [Related]
6. Service setting impact on costs for bevacizumab-treated oncology patients.
Engel-Nitz NM; Yu EB; Becker LK; Small A
Am J Manag Care; 2014 Nov; 20(11):e515-22. PubMed ID: 25730350
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
8. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
9. Better together? costs of first-line chemoimmunotherapy for advanced non-small cell lung cancer.
Kish J; Liassou D; Hartman J; Lubinga SJ; Chopra D; Feinberg B
Am J Manag Care; 2023 May; 29(5):e129-e135. PubMed ID: 37229786
[TBL] [Abstract][Full Text] [Related]
10. The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers.
Rossi A; Torri V; Garassino MC; Porcu L; Galetta D
Cancer Treat Rev; 2014 May; 40(4):485-94. PubMed ID: 24112813
[TBL] [Abstract][Full Text] [Related]
11. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
Hardtstock F; Myers D; Li T; Cizova D; Maywald U; Wilke T; Griesinger F
BMC Cancer; 2020 Mar; 20(1):260. PubMed ID: 32228520
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
15. Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer.
Cohen JT; Lin PJ; Sheinson DM; Wong WB; Wu N; Yim YM; Ramsey SD
J Oncol Pract; 2019 Nov; 15(11):e948-e956. PubMed ID: 31513478
[TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
17. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
18. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.
Dalal AA; Gagnon-Sanschagrin P; Burne R; Guérin A; Gauthier G; Small T; Niravath P
Adv Ther; 2018 Jun; 35(6):768-778. PubMed ID: 29869106
[TBL] [Abstract][Full Text] [Related]
19. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
20. Differences in Health Care Use and Costs Among Patients With Cancer Receiving Intravenous Chemotherapy in Physician Offices Versus in Hospital Outpatient Settings.
Fisher MD; Punekar R; Yim YM; Small A; Singer JR; Schukman J; McAneny BL; Luthra R; Malin J
J Oncol Pract; 2017 Jan; 13(1):e37-e46. PubMed ID: 27845870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]